Abstract
This overview presents new insights into renal cell carcinoma (RCC). The search for new target structures for targeted therapy as well as diagnostic and prognostic markers continues to remain a desirable area of research. Investigations are focusing on the use of well-established and new therapeutic agents for metastatic RCC and an increasingly liberal indication for organ-sparing surgery for renal tumors. The response to systemic treatment in metastatic RCC is also being evaluated in defined subpopulations.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Renal Cell / diagnosis*
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / pathology
-
Carcinoma, Renal Cell / therapy*
-
Combined Modality Therapy
-
Drug Delivery Systems
-
Humans
-
Kidney Function Tests
-
Kidney Neoplasms / diagnosis*
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / therapy*
-
Neoplasm Staging
-
Nephrectomy / methods
-
Organ Sparing Treatments
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Survival Rate
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Protein-Tyrosine Kinases